Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction (for specialized target groups only)

FINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient population
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news